Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,103 active trials29 approved drugs653 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03372291 | Psychological Intervention Mobile App for Patients With AML | completed | N/A | 60 | Massachusetts General HospitalOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05326516 | A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia | completed | Phase 1 | 30 | Syndax PharmaceuticalsINDUSTRY | 2 | Aug 13, 2024 | clinicaltrials |
| NCT03275636 |
| Haploidentical Donor vs mMUD in Hematological Malignancies(HAMLET) |
| completed |
| Phase 2 / Phase 3 |
| 98 |
| DKMS gemeinnützige GmbHOTHER |
| 1 |
| Aug 7, 2024 |
| clinicaltrials |
| NCT02001818 | Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia(PInNACLe) | completed | Phase 2 | 60 | Australasian Leukaemia and Lymphoma GroupOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT02668653 | Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)(QuANTUM-First) | completed | Phase 3 | 539 | Daiichi SankyoINDUSTRY | 28 | Aug 6, 2024 | clinicaltrials |
| NCT00042003 | Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec) | completed | Phase 2 | 40 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 2, 2024 | clinicaltrials |
| NCT00043381 | Decitabine Versus Supportive Care in Adults With Advanced-stage MDS | completed | Phase 3 | 160 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT03813186 | Effect of Food on Blood Levels of ASTX727 | completed | Phase 1 | 18 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT02113982 | Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 138 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Aug 1, 2024 | clinicaltrials |
| NCT02323022 | Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 3 | 618 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT03902665 | Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75 | completed | Phase 2 | 19 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06516029 | Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Asciminib | completed | — | 111 | NovartisINDUSTRY | 1 | Jul 23, 2024 | clinicaltrials |
| NCT04901416 | Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS | completed | Phase 1 | 8 | Coeptis TherapeuticsINDUSTRY | 1 | Jul 19, 2024 | clinicaltrials |
| NCT06134102 | Clinical and Laboratory Characteristics of Polycythemia Vera(PV-ARC) | completed | — | 1,150 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT02626715 | Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS | completed | Phase 2 | 21 | Randy WindreichOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT00557193 | Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 3 | 218 | Children's Oncology GroupNETWORK | 4 | Jul 15, 2024 | clinicaltrials |
| NCT02400281 | Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients | completed | Phase 1 / Phase 2 | 28 | Arog Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 3, 2024 | clinicaltrials |
| NCT04969601 | Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings(PACIFIC) | completed | Phase 1 / Phase 2 | 76 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT04835519 | Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 5 | Beijing Boren HospitalOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06463639 | FLT3 Clonal Evolution in Patients With Acute Myeloid Leukemia | completed | — | 1,213 | National Taiwan University HospitalOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT00547196 | AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders | completed | N/A | 10 | City of Hope Medical CenterOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT04629443 | Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia | completed | Phase 1 / Phase 2 | 17 | Institut de Recherches Internationales ServierOTHER | 4 | Jun 6, 2024 | clinicaltrials |
| NCT00590187 | Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients | completed | Phase 2 | 105 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 4, 2024 | clinicaltrials |
| NCT04580121 | A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420. | completed | Phase 1 | 59 | Hoffmann-La RocheINDUSTRY | 10 | Jun 3, 2024 | clinicaltrials |
| NCT04243122 | Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients(AIRPORT-MPN) | completed | Phase 2 | 44 | Ottawa Hospital Research InstituteOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT03493646 | Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486 | completed | Phase 2 | 40 | Kirby InstituteOTHER_GOV | 1 | May 28, 2024 | clinicaltrials |
| NCT06429670 | Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory(VENAURA) | completed | — | 500 | Hospices Civils de LyonOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT01995578 | Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse | completed | Phase 2 | 32 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT03333005 | Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and Neutropenia | completed | Phase 1 | 20 | Basilea PharmaceuticaINDUSTRY | 1 | May 17, 2024 | clinicaltrials |
| NCT03678493 | A Study of FMT in Patients With AML Allo HSCT in Recipients | completed | Phase 2 | 100 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT03047993 | Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT05988047 | Analysis of CMTM6 Expression in Patients With Acute Myeloid Leukemia | completed | — | 150 | University of FreiburgOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT04942730 | Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)(FluBuBe) | completed | Phase 2 | 50 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT05853445 | A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera(PAVE) | completed | — | 467 | Novartis PharmaceuticalsINDUSTRY | 1 | May 6, 2024 | clinicaltrials |
| NCT01597219 | Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers(UK-Haplo) | completed | Phase 2 | 77 | University College, LondonOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT03426605 | A Study of LAM-003 in Patients With Acute Myeloid Leukemia | completed | Phase 1 | 17 | OrphAI TherapeuticsINDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT05433532 | Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients | completed | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT02981914 | Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation | completed | Early Phase 1 | 12 | University of ChicagoOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT01751997 | Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors | completed | Phase 2 / Phase 3 | 116 | Byung-Sik ChoOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06371573 | Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms | completed | — | 45 | Federico II UniversityOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT04202003 | A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | completed | Phase 1 / Phase 2 | 105 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | Apr 15, 2024 | clinicaltrials |
| NCT02340884 | A Pilot RCT of the PRISM Intervention for AYAs With Cancer | completed | Phase 2 | 92 | Seattle Children's HospitalOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06069024 | Population Pharmacokinetic Study Based on Quantitative Pharmacology in Patients With Lenalidomide | completed | — | 38 | Qianfoshan HospitalOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT04666025 | SARS-CoV-2 Donor-Recipient Immunity Transfer | completed | — | 26 | City of Hope Medical CenterOTHER | 1 | Apr 8, 2024 | clinicaltrials |
| NCT03959241 | TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)(1703/1801) | completed | Phase 3 | 431 | Medical College of WisconsinOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT01578109 | Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 51 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2024 | clinicaltrials |
| NCT01588015 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05421091 | Special Drug Use-results Surveillance of Scemblix Tablets | completed | — | 550 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT01595295 | Registry on Hypomethylating Agents in Myeloid Neoplasms | completed | — | 1,500 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 2 | Mar 25, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Aug 13, 2024source: clinicaltrials